AR and neoplasm: The differences observed pre- and post-treatment could reflect tumor heterogeneity and biopsy sampling bias, or reflect clonal evolution wherein tumor cells harboring the intra-AR tandem duplication emerged during therapy with enzalutamide, and tumor cells harboring the AR T878A mutation became less abundant.